Home / Letter From The Editor / May 10, 2018

May 10, 2018

May 10, 2018
 

The use of SGLT-2 inhibitors has grown over the past couple of years as more information is released about them. Many of you reading this special edition have had great successes with these drugs, and there seems to be more data to show why they are so important. However, when Steve and I reached out in a random survey of practitioners, we found that there were still a large percentage of our readers who have never prescribed in this class before. This month we would like to offer a two part series on how to determine if your patients would be good candidates for SGLT-2 Therapy and how to work this class of drugs into their regimen.

 

Dave Joffe

Editor-in-chief